{"entity":{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","aka":[],"tldr":"The trial that showed Ph-positive ALL can be treated with a pill plus an immunotherapy and no chemotherapy, with 95% of patients alive at 18 months.","summary":"63 patients (median age 54): molecular response 60% after two blinatumomab cycles rising with further cycles; 18-month OS 95%, DFS 88%; only half went to transplant. NEJM 2020. Four-year update: OS ~80%, DFS ~75%, with IKZF1-plus and T315I relapses. Successor trials (GIMEMA ALL2820 with ponatinib) and MD Anderson ponatinib-blinatumomab series extend the chemotherapy-free approach.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT02744768","url":"https://clinicaltrials.gov/study/NCT02744768"},{"label":"NEJM 2020","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2016272"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["bcr-abl","cd19"],"drugs":["dasatinib","blinatumomab"],"companies":["gimema"],"institutions":[],"pathways":[],"terms":["ph-positive-all"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02744768","phase":"2","setting":"Newly diagnosed Ph-positive ALL, adults of all ages: dasatinib induction followed by blinatumomab, no systemic chemotherapy","sponsor":"GIMEMA","result":"18-month OS 95%, DFS 88%.","started":"2017-05-31","startedType":"actual","yearReported":2020,"enrolled":63,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 18 months","unit":"%","arms":[{"name":"Dasatinib → blinatumomab","n":63,"value":95}],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2016272"},{"endpoint":"Disease-free survival at 18 months","primary":true,"unit":"%","arms":[{"name":"Dasatinib → blinatumomab","value":88}],"source":"https://doi.org/10.1056/NEJMoa2016272"}],"replication":"MD Anderson ponatinib + blinatumomab phase 2 (Jabbour et al.) reproduced near-universal molecular remission without chemotherapy; randomised confirmation (GIMEMA ALL2820, EWALL) pending."},"route":"/trials/d-alba/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/"}],"company":[{"id":"gimema","kind":"company","name":"GIMEMA","route":"/companies/gimema/"}],"term":[{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/"}],"pairing":[{"id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/"}],"idea":[{"id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/"}]}}